Oral Semaglutide Effectively Manages Type 2 Diabetes in Real-World Mexican Adults

Oral semaglutide, a GLP-1 receptor agonist, is a well-established treatment for Type 2 Diabetes (T2D). While its efficacy has been proven in controlled clinical trials, understanding its performance in diverse, real-world populations is crucial for broader clinical application. This study specifically aimed to evaluate the effectiveness and safety of once-daily oral semaglutide in Mexican adults with T2D under routine clinical conditions.

The study revealed significant improvements in key metabolic parameters among the participants. The mean HbA1c (a measure of long-term blood sugar control) decreased notably by 1.5% from a baseline average of 8.2% to 6.7% at the 24-week mark (p<0.001). Patients also experienced a substantial mean body weight reduction of 5.8 kg (6.5% of their baseline body weight, p<0.001), highlighting a significant positive impact on obesity, a common comorbidity in T2D. Furthermore, 48% of patients successfully achieved an HbA1c target of <7.0%, a marked improvement from only 12% at the study's commencement. The incidence of gastrointestinal adverse events was consistent with previous clinical trials, with 22% reporting mild nausea and 8% experiencing diarrhea, leading to discontinuation in only 3% of participants.